<DOC>
	<DOC>NCT00152009</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17</brief_summary>
	<brief_title>Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects with a primary diagnosis of ADHD Male or nonpregnant female subject who agrees to comply with any applicable contraceptive requirements Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD) with significant symptoms History of seizure during the last 2 years Subject has any specific cardiac condition or family history of significant cardiac condition Subject is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>